BridgeBio Pharma Files 8-K
Ticker: BBIO · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, disclosure
TL;DR
BridgeBio filed an 8-K, no juicy details yet.
AI Summary
BridgeBio Pharma, Inc. filed an 8-K on September 10, 2024, reporting an "Other Event." The filing does not contain specific details about the event, financial figures, or material developments, but it is a standard disclosure for significant corporate events.
Why It Matters
This 8-K filing indicates that BridgeBio Pharma, Inc. has reported a significant event to the SEC, which could potentially impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- September 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 3160 Porter Dr., Suite 250 (address) — Principal Executive Offices
- Palo Alto, CA 94304 (address) — Principal Executive Offices
FAQ
What specific event is BridgeBio Pharma, Inc. reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the event itself within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 10, 2024.
What is the state of incorporation for BridgeBio Pharma, Inc.?
BridgeBio Pharma, Inc. is incorporated in Delaware.
What is the principal executive office address for BridgeBio Pharma, Inc.?
The principal executive office is located at 3160 Porter Dr., Suite 250, Palo Alto, CA 94304.
Is this filing related to financial statements or exhibits?
Yes, the filing information indicates 'Financial Statements and Exhibits' as an item information, alongside 'Other Events'.
Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-10 18:23:18
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
Filing Documents
- ef20035749_8k.htm (8-K) — 29KB
- ef20035749_ex99.htm (EX-99.1) — 21KB
- 0001140361-24-040755.txt ( ) — 190KB
- bbio-20240910.xsd (EX-101.SCH) — 4KB
- bbio-20240910_lab.xml (EX-101.LAB) — 21KB
- bbio-20240910_pre.xml (EX-101.PRE) — 16KB
- ef20035749_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On September 10, 2024, BridgeBio Pharma, Inc. issued a press release titled, "BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)." A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release titled, "BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: September 10, 2024 By: /s/ Brian C. Stephenson Brian C. Stephenson Chief Financial Officer